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ABSTRACT	  Liver	   fibrogenesis	   is	  a	  process	   tightly	  controlled	  by	  endogenous	  anti-­‐	  and	  pro-­‐fibrogenic	  factors.	   Interferon	   gamma	   (IFNγ)	   is	   a	   potent	   anti-­‐fibrogenic	   cytokine	   in	   vitro	   and	  might	  therefore	   represent	   a	   powerful	   therapeutic	   entity.	   However,	   its	   poor	   pharmacokinetics	  and	   adverse	   effects,	  due	   to	   the	   presence	  of	   IFNγ	   receptors	   on	  nearly	   all	   cells,	  prevented	   its	   clinical	  application	  so	  far.	  We	  hypothesized	   that	  delivery	   of	   IFNγ	  specifically	   to	   the	  disease-­‐inducing	  cells	  and	   concurrently	  avoiding	   its	   binding	  to	   non-­‐target	   cells	   might	   increase	   therapeutic	   efficacy	   and	   avoid	   side	   effects.	   We	  conjugated	  IFNγ	  to	  a	  cyclic	  peptide	  recognizing	  the	  platelet-­‐derived	  growth	  factor	  receptor	  beta	  (PDGFβR),	  which	  is	  strongly	  up-­‐regulated	  on	  activated	  hepatic	  stellate	  cells	  (HSC),	  the	  key	  effector	  cells	  responsible	  for	  hepatic	  fibrogenesis.	  The	  IFNγ	  conjugates	  were	  analyzed	  
in	  vitro	  for	  PDGFβR-­‐specific	  binding	  and	  biological	  effects	  and	  in	  vivo	  in	  acute	  (early)	  and	  chronic	  (progressive	  and	  established)	  carbon	  tetrachloride	  induced	  liver	  fibrosis	  in	  mice.	  The	  targeted	  IFNγ	  construct	  showed	  PDGFβR-­‐specific	  binding	  to	  fibroblasts	  and	  HSC	  and	  inhibited	  their	  activation	  in	  vitro.	  In	  vivo,	  the	  targeted-­‐IFNγ	  construct	  attenuated	  local	  HSC	  activation	   in	   acute	   liver	   injury	  model.	   In	   the	   established	   liver	   fibrosis	  model,	   it	   not	   only	  strongly	   inhibited	  fibrogenesis	  but	  also	   induced	  fibrolysis.	   In	  contrast,	  non-­‐targeted	  IFNγ	  was	  ineffective	  in	  both	  models.	  Moreover,	  in	  contrast	  to	  unmodified	  IFNγ,	  our	  engineered	  targeted	   IFNγ	   did	   not	   induce	   IFNγ-­‐related	   side	   effects	   such	   as	   systemic	   inflammation,	  hyperthermia,	   elevated	   plasma	   triglyceride	   levels	   and	   neurotropic	   effects.	   Conclusion:	  This	  study	  presents	  a	  novel	  HSC	  targeted	  engineered	  IFNγ,	  which	   in	  contrast	  to	  systemic	  IFNγ,	  blocked	   liver	   fibrogenesis	  and	   is	  devoid	  of	  side	  effects	  by	  specifically	  acting	  on	   the	  key	  pathogenic	  cells	  within	  the	  liver.	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1.	  INTRODUCTION	  Liver	   cirrhosis,	   characterized	   by	   the	   extensive	   accumulation	   of	   an	   abnormal	  extracellular	  matrix	  is	  the	  major	  cause	  of	  liver-­‐related	  morbidity	  and	  mortality	  worldwide	  (1,	  2).	  Except	  for	  an	  effective	  treatment	  of	  the	  underlying	  etiology,	  which	  is	  an	  option	  for	  some	   patients,	   there	   exists	   no	   clinically	   proven	   anti-­‐fibrotic	   therapy	   to	   prevent	  progression	   of	   chronic	   liver	   disease	   to	   cirrhosis	   or	   to	   its	   regression	   (3,	   4).	   Activated	  hepatic	   stellate	   cells	   and	  portal	   fibroblasts	   (collectively	  named	  activated	  hepatic	   stellate	  cells,	  HSC)	  are	  the	  main	  effector	  cells	  of	  liver	  fibrogenesis,	  producing	  most	  of	  the	  excessive	  extracellular	  matrix	  (ECM)	  such	  as	  fibrillar	  collagens	  (5).	  Following	  liver	  injury,	  release	  of	  several	  fibrogenic	  factors	  by	  inflammatory	  cells,	  bile	  duct	  epithelia	  or	  hepatocytes,	  such	  as	  transforming	  growth	  factor-­‐beta	  (TGFβ)	  or	  platelet-­‐derived	  growth	  factor	  (PDGF)	  activate	  HSC	   to	   transform	   to	   contractile	   myofibroblastic	   cells	   characterized	   by	   enhanced	  proliferation	  and	  ECM	  production	  (5).	  There	  are	  only	  a	  few	  cytokines	  such	  as	  interferon-­‐alpha	   (IFN-­‐α)	   and	   interferon-­‐gamma	   (IFNγ)	   that	   can	   attenuate	   fibrogenic	   processes	   and	  have	  been	  explored	  as	  potential	  therapeutics	  (6).	  However,	  while	  IFNα	  and	  especially	  IFNγ	  are	  highly	  effective	  anti-­‐fibrotic	  agents	   in	  vitro	  and	   in	  some	  animal	  models	   in	  vivo	  (6,	  7),	  their	   anti-­‐fibrotic	   potential	   in	   clinical	   trials	  has	  been	  disappointing,	   due	   to	   poor	   efficacy	  and	  unwanted	  off-­‐target	  effects	  (8,	  9),	  related	  to	  the	  ubiquitous	  presence	  of	  IFNγ	  receptor	  (IFNγR)	  on	  all	  cells	  except	  erythrocytes	  (10).	  	  IFNγ	   is	  a	  pleiotropic	  pro-­‐inflammatory	  Th1	  cytokine	  produced	  by	  activated	  immune	  cells	   (10).	   It	   has	   been	   tested	   for	   the	   treatment	   of	   viral,	   immunological	   and	   malignant	  diseases	  (11)	  due	  to	  its	  anti-­‐viral,	  immune-­‐modulatory	  and	  anti-­‐proliferative	  activities.	  In	  addition,	  several	  clinical	  studies	  have	  explored	  the	  potential	  role	  of	  systemic	  IFNγ	  in	  renal,	  pulmonary	   and	   liver	   fibrosis	   (8,	   9,	   12).	  However,	   its	   limited	   efficiency	   associated	  with	   a	  short	   circulation	   half-­‐life	   and	   undesirable	   systemic	   side	   effects	   has	   limited	   its	   clinical	  utility.	  Many	  attempts	  to	  prolong	  the	  IFNγ	  half-­‐life	  or	  to	  enhance	  its	  activity	  through	  slow	  release	   by	   incorporation	   into	   nanoparticles,	   liposomes,	   microspheres	   or	   elastomers	   did	  not	   lead	   to	   a	   significant	   improvement	   (13,	   14).	   No	   approach	   of	   cell-­‐specific	   delivery	   of	  IFNγ	   has	   been	   reported,	   although	   in	   vivo	   disease	   activity	   is	   controlled	   by	   its	   local	  production.	   Experimental	   therapies,	   mimicking	   this	   local	   production,	   are	   therefore	  attractive.	  In	  the	  present	  study,	  we	  chemically	  engineered	  IFNγ	  by	  directing	  it	  to	  another	  target	  receptor,	  PDGFβR,	  that	  is	  abundantly	  expressed	  only	  on	  activated	  HSC	  during	  fibrogenesis	  (15,	   16).	   IFNγ	   was	   covalently	   conjugated	   to	   a	   PDGFβR-­‐recognizing	   cyclic	   peptide	   (17)	  (PPB)	  either	  directly	  or	  indirectly	  using	  a	  PEG	  linker.	  PPB	  cyclic	  peptide	  (*CSRNLIDC*)	  has	  been	   developed	   by	   our	   group	   (17)	   and	   extensively	   studied	   for	   PDGFβR-­‐specific	   drug	  delivery	  e.g.	  to	  tumors	  (18).	  The	  PPB-­‐modified	  IFNγ	  constructs	  were	  characterized	  in	  vitro	  for	  their	  biological	  activity	  in	  fibroblasts	  and	  HSC.	  In	  vivo,	  the	  targeted	  constructs	  showed	  high	  specific	  binding	  to	  the	  target	  cells,	   inhibited	  HSC	  activation	  and	  progression	  of	   liver	  fibrosis/cirrhosis	  in	  acute	  and	  chronic	  CCl4-­‐induced	  fibrosis	  models.	  Notably,	  the	  targeted	  IFNγ	  construct	  were	  devoid	  of	  unwanted	  IFNγ-­‐related	  side	  effects.	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2.	  MATERIALS	  AND	  METHODS	  
2.1.	  Human	  liver	  specimens	  Human	   liver	   specimens	   were	   obtained	   from	   liver	   transplanted	   patients	   suffering	  from	   liver	   cirrhosis	   and	   were	   anonymously	   provided	   by	   the	   Department	   of	   Pathology	  (University	   medical	   center	   Groningen	   UMCG,	   The	   Netherlands).	   Control	   tissue	   was	  obtained	  from	  the	  unaffected	  part	  of	  liver	  from	  transplanted	  patients.	  Necessary	  approvals	  were	  obtained	  from	  hospital	  Medical	  Ethics	  Committee.	  
2.2.	  Cell	  lines	  	  Mouse	   3T3	   fibroblasts	   and	   RAW	   macrophages	   were	   obtained	   from	   the	   American	  Type	  Culture	  Collection	  (ATCC).	  Human	  Hepatic	  stellate	  cells	  (LX2)	  were	  kindly	  provided	  by	   Prof.	   Scott	   Friedman	   (Mount	   Sinai	   Hospital,	   New	   York).	   RAW	  macrophages	   and	   3T3	  fibroblasts	   were	   cultured	   in	   Dulbecco’s	   modified	   Eagle’s	   medium	   (DMEM,	   Invitrogen,	  Carlsbad,	   CA)	   supplemented	   with	   10%	   FBS.	   LX2	   were	   cultured	   in	   DMEM-­‐Glutamax	  (Invitrogen)	  supplemented	  with	  10%	  FBS.	  	  
2.3.	  Synthesis	  of	  Interferon	  gamma	  conjugates	  	  IFNγ	   conjugates	   were	   synthesized	   by	   either	   direct	   chemical	   coupling	   of	   PDGFβ	  receptor	   recognizing	   peptide	   (PPB)	   via	   N-­‐[γ-­‐maleimidobutyryloxy]	   succinimide	   ester	  (GMBS;	   Sigma,	   St.	   Louis,	   MO)	   to	   generate	   IFNγ-­‐PPB	   or	   by	   indirect	   conjugation	   using	  bifunctional	  PEG	  molecule	  (Mal-­‐PEG-­‐SCM,	  2	  KDa,	  Creative	  PEGworks,	  Winston	  Salem,	  NC)	  to	   synthesize	   IFNγ-­‐PEG-­‐PPB.	   As	   a	   control	   IFNγ-­‐PEG	   was	   synthesized	   using	   mono-­‐functional	   PEG	   (mPEG-­‐SMB,	   2	   KDa,	   Nektar	   therapeutics).	   The	   detailed	   syntheses	   and	  characterization	  using	  western	  blotting	  are	  described	  in	  supplementary	  data.	  
2.4	  Immunohistochemistry	  and	  immunofluorescence	  The	   detailed	   protocol	   for	   immuno-­‐histochemistry	   and	   immuno-­‐flourescence	   is	  described	   in	   supplementary	   data.	   The	   antibodies	   used	   in	   the	   study	   are	   listed	   in	  
Supplementary	  Table	  1.	  
2.5.	  Nitric	  oxide	  (NO)	  release	  bioassay	  in	  RAW	  macrophages	  	  The	  bioactivity	  of	  IFNγ	  and	  IFNγ	  conjugates	  was	  assessed	  by	  measuring	  accumulation	  of	  nitrite	  NO2,	  a	  stable	  nitric	  oxide	  (NO)	  metabolite	  produced	  by	  RAW	  macrophages	  (19).	  Briefly,	  cells	  seeded	  in	  96-­‐well	  plates	  were	  incubated	  with	  different	  concentrations	  of	  IFNγ	  and	  IFNγ	  conjugates.	  After	  24h,	  the	  secreted	  nitrite	  was	  measured	  as	  absorbance	  at	  550nm	  using	   Greiss	   reagent	   (1%	   sulfanilamide;	   0.1%	   naphthylethylendiamine	   dihydrochloride;	  3%	  H3PO4).	  	  
2.6.	   In	   vitro	   binding	   and	   effects	   of	   the	   IFNγ 	   conjugates	   in	   mouse	   fibroblasts	   and	  
human	  HSC	  	  Cells	   were	   seeded	   in	   Lab-­‐Tek	   (Nunc,	   Roskilde,	   Denmark)	   or	   in	   24-­‐well	   plates	   and	  cultured	  overnight.	  For	  binding	  study,	  cells	  were	  incubated	  with	  IFNγ	  or	  IFNγ	  conjugates	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(1µg/ml).	   To	   block	   the	   PDGFβR-­‐mediated	   binding,	   anti-­‐PDGFβR	   IgG	   (Santa	   Cruz	  Biotechnology,	  Santa	  Cruz,	  CA,	  USA)	  was	  added	  1h	  before	  IFNγ	  conjugates.	  After	  2h,	  cells	  were	  fixed	  and	  immunofluorescent	  staining	  for	  PPB	  and	  IFNγ	  was	  performed.	  	  To	   assess	   effects	   on	   fibrotic	   parameters,	   cells	  were	   starved	   for	   24h	   and	   incubated	  with	   IFNγ	   and	   IFNγ	   conjugates	   with	   5ng/ml	   of	   human	   recombinant	   TGFβ1	   (Roche,	  Mannheim,	  Germany)	  for	  48h.	  Subsequently,	  cells	  were	  fixed	  and	  stained	  for	  collagen	  I	  and	  III.	  To	  assess	  effects	  on	  proliferation,	  cells	  were	  starved	  for	  24h	  and	  incubated	  with	  IFNγ	  and	   IFNγ	   conjugates	   plus	   50ng/ml	   of	   human	   recombinant	   PDGF	   (Peprotech)	   for	   48h.	  Subsequently,	  cells	  were	  incubated	  with	  0.25μCi/ml	  of	  thymidine	  3[H]	  for	  6h,	  after	  which	  the	  cells	  were	  washed	  thoroughly,	  fixed	  with	  5%	  TCA,	  lysed	  with	  1ml	  of	  1M	  NaOH,	  mixed	  with	  4ml	  of	  scintillation	  fluid	  and	  measured	  using	  scintillation	  counter.	  All	  measurements	  were	  performed	  in	  duplicates	  in	  three	  independent	  experiments.	  
2.7.	  CCl4-­‐induced	  acute	  liver	  injury	  mouse	  model	  Male	  C57BL/6	  mice	  (20-­‐22g)	  were	  treated	  with	  a	  single	  intra-­‐peritoneal	  injection	  of	  olive	   oil	   or	   CCl4	   (1ml/kg	   in	   olive	   oil)	   at	   day	   1.	   At	   day	   2	   and	   day	   3,	   CCl4-­‐treated	   mice	  intravenously	   received	   different	   treatments	   or	   PBS	   (n=6	   per	   group).	   At	   day	   4,	   all	   mice	  were	  sacrificed;	  blood	  and	  different	  organs	  were	  collected	  for	  subsequent	  analysis.	  	  For	  in	  vivo	  bio-­‐distribution	  of	  the	  conjugates	  (n=6	  per	  group),	  mice	  were	  treated	  with	  different	  constructs	  10min,	  prior	  to	  sacrifice	  on	  day	  4	  after	  CCl4	  injection.	  	  
2.8.	  CCl4-­‐induced	  advanced	  liver	  fibrosis	  mouse	  model	  Male	   balb/c	  mice	   (20-­‐22g)	   were	   treated	   with	   olive	   oil	   or	   increasing	   doses	   of	   CCl4	  (week	  1:	  0.5	  ml/kg;	  week	  2:	  0.8	  ml/kg	  and	  week	  3-­‐8:	  1ml/kg	  prepared	  in	  olive	  oil)	  twice	  weekly	  by	  intra-­‐peritoneal	  injections	  for	  8	  weeks	  as	  previously	  described	  (20).	  In	  week	  7	  and	   8,	   mice	   were	   treated	   intravenously	   with	   PBS,	   IFNγ,	   IFNγ-­‐PEG	   or	   IFNγ-­‐PEG-­‐PPB	  (2.5µg/mice,	   thrice	   per	  week),	   n=6	   per	   group	  while	   continuing	   CCl4	   injections.	   All	  mice	  were	   sacrificed	   at	   week	   8;	   blood	   and	   different	   organs	   were	   collected	   for	   subsequent	  measurements.	   ALT,	   AST	   and	   plasma	   triglycerides	   levels	   were	   measured	   by	   standard	  automated	   laboratory	  methods.	   Plasma	   levels	   of	   TNF-­‐α	   and	   IL-­‐6	  were	   analyzed	   using	   a	  cytometric	   bead	   array	   (BD	   Pharmingen,	   San	   Diego,	   CA,	   USA)	   according	   to	   the	  manufacturer’s	   instructions.	   IFNγ-­‐induced	   fever	  was	   determined	   (21)	   by	  measuring	   the	  rectal	  temperature	  after	  30min	  of	  treatments	  using	  a	  digital	  thermometer	  with	  lubricated	  thermocouple	   inserted	   1.5cm	   into	   the	   rectum	   of	   mice.	   Hepatic	   collagen	   content	   was	  determined	  by	  liver	  hydroxyproline	  assay	  as	  reported	  with	  minor	  modifications	  (22).	  The	  relative	  hydroxyproline	  (mg/g	  liver)	  was	  calculated	  based	  on	  individual	  liver	  weights.	  All	  the	  experimental	  protocols	   for	  animal	  studies	  have	  been	  approved	  by	  the	  Animal	  Ethical	  Committee	  of	  the	  University	  of	  Groningen.	  
2.9.	  Quantitative	  real-­‐time	  PCR	  The	  detailed	  protocol	   for	  quantitative	   real-­‐time	  PCR	   is	  described	   in	   supplementary	  data.	  The	  primers	  used	  are	  listed	  in	  Supplementary	  Table	  2.	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2.10.	  Statistical	  analyses	  	  Data	   are	   presented	   as	   mean	   ±	   standard	   error	   mean	   (SEM).	   Multiple	   comparisons	  between	  different	  groups	  were	  performed	  by	  one-­‐way	  ANOVA	  with	  Bonferroni	  post-­‐test.	  
3.	  RESULTS	  
3.1.	  PDGFβ 	  receptor	  expression	  on	  fibroblasts	  and	  hepatic	  stellate	  cells	  
	  We	   first	   examined	   the	   expression	   of	   PDGFβR,	   in	  mouse	   and	   human	   fibrotic	   livers.	  PDGFβR	   was	   highly	   up-­‐regulated	   in	   areas	   of	   active	   fibrogenesis	   (Figure	   1A,	   1B)	   and	  specifically	   co-­‐localized	  with	  desmin-­‐positive	  HSC	   (Figure	  1C).	  Conversely,	  PDGFβR	  was	  virtually	   absent	   in	   normal	   livers	   and	   other	   organs	   (Figure	   1D).	   High	   expression	   of	  PDGFβR	   on	   activated	   HSC	   in	   fibrotic	   livers	   relative	   to	   other	   tissues	   and	   cells	   known	   to	  express	   PDGFβR	   indicates	   that	   this	   receptor	   is	   an	   appropriate	   target	   for	   HSC-­‐specific	  delivery	  in	  active	  liver	  fibrogenesis. 	  
Figure	  1.	  PDGFβ	  receptor	  expression	   in	  human	  and	  mouse	   livers	  and	  other	  mouse	  organs	  
(lung,	   kidney,	   heart	   and	   spleen),	   PDGFβR-­‐targeted	   IFNγ 	   constructs	   and	   their	   in	   vitro	  
biological	   activity.	   (A)	   Representative	   photomicrographs	  depicting	   up-­‐regulation	   of	   PDGFβR	   in	  cirrhotic	  human,	  and	  in	  CCl4-­‐fibrotic	  mouse	  liver	  sections	  as	  compared	  to	  normal	  livers.	  Scale	  bars,	  100μm.	   (B)	   PDGFβR	   transcripts	   were	   significantly	   elevated	   in	   the	   fibrotic	   livers.	   #p<0.05	   and	  ##p<0.01	  versus	  PBS-­‐treated	  olive	  oil	   (normal)	   group.	   (C)	   Fluorescent	  pictures	  of	   liver	   sections	  showing	   co-­‐localization	   of	   HSC	   and	   PDGFβR	   in	   mouse	   (x100)	   and	   human	   (x200)	   fibrotic	   livers	  stained	   for	   desmin	   (HSC	   marker,	   green),	   PDGFβR	   (red)	   and	   nuclei	   (blue).	   (D)	   PDGFβR-­‐stained	  tissue	  sections	   from	  CCl4-­‐fibrotic	  mice	  showing	  negligible	  expression	  of	  PDGFβR	  in	  other	  tissues.	  Scale	  bars,	  100	  μm.	  (E)	  Schematic	  representation	  of	  the	  chemically	  engineered	  IFNγ	  conjugates.	  (F)	  Nitrogen	  oxide	  (NOx)	  release	  in	  mouse	  RAW	  macrophages	  (n=3)	  after	  incubation	  with	  unmodified	  native	   IFNγ	   and	   IFNγ	   conjugates	   showing	   that	   IFNγ	   conjugates	   retain	   their	   biological	   activity	  relative	  to	  unmodified	  IFNγ.	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3.2.	  Syntheses	  and	  in	  vitro	  characterization	  of	  targeted	  IFNγ 	  constructs	  To	   target	   IFNγ	   to	   HSC,	   we	   modified	   IFNγ	   with	   PDGFβR-­‐recognizing	   cyclic	   peptide	  (PPB)	  using	  different	  conjugation	  strategies	  as	   illustrated	  in	  Figure	  1E.	  PPB	  was	  directly	  conjugated	  to	   IFNγ	   (IFNγ-­‐PPB)	  or	  via	  a	  2	  KDa	  hydrophilic	  hetero-­‐bifunctional	  PEG	   linker	  (IFNγ-­‐PEG-­‐PPB).	   In	  addition,	  we	  synthesized	  IFNγ-­‐PEG	  as	  a	  control.	  The	  synthesis	  details	  are	   illustrated	   in	   Supplementary	   Figure	   1.	   The	   synthesized	   conjugates	   were	  characterized	   by	   Western	   blot	   analyses	   with	   anti-­‐IFNγ	   and	   anti-­‐PPB	   antibodies	  (Supplementary	  Figure	  2).	  Since	   chemical	  modifications	   of	   cytokines	   can	   diminish	   their	   biological	   activity,	  we	  examined	  the	  activity	  of	  the	  IFNγ	  conjugates	  compared	  to	  unmodified	  IFNγ	  in	  mouse	  RAW	  macrophages.	  These	  cells	  express	  the	  IFNγR	  but	  lack	  the	  PDGFβR.	  IFNγ	  and	  its	  constructs	  IFNγ-­‐PPB,	   IFNγ-­‐PEG	  and	   IFNγ-­‐PEG-­‐PPB	  all	   induced	  a	   similar	  dose-­‐dependent	   increase	   in	  nitric	  oxide	  (NOx)	  release	  in	  RAW	  cells	  (Figure	  1F).	  There	  was	  no	  significant	  difference	  in	  dose-­‐response	   slopes,	   demonstrating	   that	   all	   IFNγ	   conjugates	   retained	   full	   biological	  activity.	  	  
3.3.	   In	   vitro	   binding	   and	   effects	   of	   the	   targeted-­‐IFNγ 	   conjugates	   in	   mouse	   3T3	  
fibroblasts	  and	  human	  LX2	  hepatic	  stellate	  cells	  IFNγ	   binds	   to	   its	   receptor,	  which	   is	   strict	   species	   specific	  while	   PDGFβR	  binding	   is	  not.	   In	   order	   to	   discriminate	   between	   IFNγR-­‐	   and	   PDGFβR-­‐mediated	   bindings,	   we	   used	  mouse	  NIH3T3	  fibroblasts,	  primary	  rat	  HSC	  and	  human	  LX2	  hepatic	  stellate	  cells.	  Results	  confirmed	   the	   species	   specificity	   of	   IFNγ;	   mouse	   IFNγ	   and	   mouse	   derived	   IFNγ-­‐PEG	  showed	  binding	  to	  mouse	  3T3	  fibroblasts	  (Figure	  2A)	  but	  not	  to	  rat	  HSC	  and	  human	  HSC	  (Figure	   2B;	   Supplementary	   Figure	   3).	   However,	   PPB-­‐modified	  mouse	   IFNγ	   conjugates	  showed	   high	   binding	   to	   mouse,	   rat	   and	   human	   cells	   (Figure	   2A,	   2B;	   Supplementary	  
Figure	  3)	  which	  was	  almost	  completely	  blocked	  with	  anti-­‐PDGFβR	  IgG	  (Figure	  2B).	  This	  demonstrates	   the	   specific	   binding	   of	   PPB-­‐modified	   IFNγ	   constructs	   to	   PDGFβR,	  which	   is	  species	  non-­‐specific.	  Subsequently,	  we	  investigated	  the	  anti-­‐fibrotic	  effects	  of	  the	  constructs	  in	  mouse	  3T3	  fibroblasts	   and	   in	   human	   HSC	   after	   activation	   with	   TGFβ.	   Both	   mouse	   IFNγ	   and	   IFNγ	  conjugates	  induced	  significant	  reduction	  in	  collagen	  expression	  in	  mouse	  cells	  (Figure	  2C,	  
2D).	   In	   addition,	   mouse	   IFNγ	   and	   IFNγ	   conjugates	   inhibited	   PDGF-­‐induced	   cell	  proliferation	   in	   3T3	   fibroblasts	   as	   assessed	   by	   thymidine	   incorporation	   assays	   (Figure	  
2E).	   Interestingly,	   in	  human	  LX2	   cells,	  TGFβ1−induced	   collagen	  expression	  was	   strongly	  inhibited	   by	   treatment	   with	   the	   PDGFR-­‐specific	   IFNγ	   constructs	   (Figure	   2C,	   2D),	   while	  unmodified	   mouse	   IFNγ	   and	   IFNγ-­‐PEG	   did	   not	   induce	   any	   effect	   in	   human	   cells	   due	   to	  species	  differences.	  These	  results	  clearly	  demonstrate	  that	  mouse	  IFNγ	   that	   is	   inactive	  in	  human	  cells	  can	  become	  biologically	  active	  in	  other	  species	  by	  directing	  it	  to	  the	  PDGFβR.	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3.4.	  In	  vivo	  localization	  of	  HSC	  targeted	  IFNγ 	  constructs	  The	   tissue	  bio-­‐distribution	  of	   human	   serum	  albumin	   (HSA)-­‐modified	  PPB	  has	  been	  previously	  extensively	   investigated	  by	  our	  group	  using	  radiolabeled	  and	   imaging	  studies	  showing	   high	   distribution	   of	   PPB-­‐HSA	   to	   fibrotic	   livers	   and	   to	   PDGFβR-­‐expressing	  activated	   hepatic	   stellate	   cells	   (17).	   To	   determine	   whether	   our	   PPB-­‐modified	   IFNγ	  constructs	  specifically	  accumulate	  in	  HSC	  in	  vivo,	  IFNγ	  and	  IFNγ	  conjugates	  (5	  μg/mouse)	  were	  administered	  to	  mice	  that	  had	  received	  a	  single	  intra-­‐peritoneal	  injection	  of	  CCl4	  and	  their	   localization	   was	   analyzed	   after	   10	   min	   (Figure	   3A).	   Liver	   uptake	   and	   cellular	  distribution	  were	   determined	   by	   double	   staining	   for	   desmin	   (HSC	  marker)	   and	   peptide,	  PPB.	   IFNγ-­‐PPB	   and	   IFNγ-­‐PEG-­‐PPB	   largely	   co-­‐localized	   with	   desmin-­‐positive	   cells,	   while	  they	  were	  absent	   in	  non-­‐damaged	  areas	  depicted	  by	  arrows	  (Figure	  3A).	  No	  co-­‐staining	  studies	  could	  be	  performed	  for	  exogenously	  administered	  IFNγ	  due	  to	  endogenous	  IFNγ.	  	  
Figure	  2.	  In	  vitro	  PDGFβR-­‐specific	  binding	  and	  anti-­‐fibrotic	  effects	  of	  targeted-­‐IFNγ 	  conjugates	  
in	  mouse	  3T3	  fibroblasts	  and	  human	  hepatic	  stellate	  cells.	  (A)	  Fluorescent	  photographs	  (x400)	  showing	   binding	   of	   IFNγ-­‐PEG,	   IFNγ-­‐PPB	   or	   IFNγ-­‐PEG-­‐PPB	   to	   mouse	   NIH3T3	   fibroblasts.	   (B)	  Fluorescent	   photographs	   (x200)	   showing	   binding	   of	   targeted	   mouse-­‐derived	   IFNγ	   conjugates	   to	  human	  HSC	  (LX2)	  and	  blocking	  of	  PDGFβR-­‐specific	  binding	  by	  PDGFβR	  antibody.	  Mouse	   IFNγ-­‐PEG	  did	  not	  show	  any	  binding	  to	  human	  LX2	  cells	  due	  to	  species	  differences.	  (C	  and	  D)	  Representative	  pictures	  (C)	  and	  quantitative	  analysis	  (D)	  of	  collagen	  I/III	  stained	  LX2	  and	  3T3	  cells,	  incubated	  with	  TGFβ	  (5ng/ml)	   in	  combination	  with	   IFNγ	  or	   IFNγ-­‐conjugates	   (1µg/ml).	  (E)	  Bars	  represent	   the	  cell	  proliferation	   (thymidine	   incorporation)	   after	   incubation	   with	   PDGFBB	   (50ng/ml)	   in	   combination	  with	   IFNγ	   or	   IFNγ-­‐conjugates	   (1µg/ml)	   in	  3T3	   fibroblasts.	  The	  groups	  were	  normalized	   to	   control	  cells	   (untreated).	   In	   3T3	   cells,	   unmodified	   mouse	   IFNγ	   and	   IFNγ	   conjugates	   caused	   a	   significant	  reduction	   of	   TGFβ-­‐induced	   collagen	   expression	   and	   PDGFBB-­‐induced	   proliferation.	   However,	   in	  human	   LX2	   cells,	   only	   PPB-­‐modified	   IFNγ	   conjugates	   attenuated	   collagen	   expression	   while	  unmodified	  mouse	  IFNγ	  and	  IFNγ-­‐PEG	  did	  not	  cause	  any	  reduction	  due	  to	  species	  restriction.	  Scale	  bars,	   200μm.	   ##p<0.01	   versus	   untreated	   cells;	   *p<0.05	   and	   **p<0.01	   versus	   TGFβ-­‐treated	   or	  PDGFBB-­‐treated	  cells	  (n=3).	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We	   also	   assessed	   major	   histocompatibility	   class	   II	   (MHC-­‐II)	   expression,	   which	   is	  known	  to	  be	  up-­‐regulated	  by	  IFNγ	  (23),	  to	  assess	  the	  biological	  activity	  of	  the	  conjugates	  in	  livers.	  IFNγ-­‐PEG-­‐PPB	  treatment	  induced	  a	  remarkable	  up-­‐regulation	  in	  MHC-­‐II	  expression	  (p<0.001)	   (Figure	   3B,	   3C)	   within	   the	   damaged	   areas	   that	   were	   characterized	   by	  accumulation	  of	  activated	  HSC	  (Figure	  3D).	  	  
3.5.	  Effects	  of	  targeted	  IFNγ 	  in	  acute	  CCl4-­‐induced	  liver	  injury	  	  IFNγ,	   IFNγ-­‐PEG	   and	   targeted-­‐IFNγ	   conjugates	   (IFNγ-­‐PPB	   and	   IFNγ-­‐PEG-­‐PPB)	   were	  subsequently	  evaluated	   for	   their	  anti-­‐fibrotic	  effects	   in	   the	  acute	  CCl4	   liver-­‐injury	  model.	  Only	   IFNγ-­‐PEG-­‐PPB	   conjugate	   significantly	   attenuated	   collagen	   I	   and	  α-­‐SMA	   expression	  (p<0.05;	   Figure	   4A,	   4B).	   Apart	   from	   collagen	   expression	   and	   deposition,	   the	   balance	  between	   collagen	   degrading	   matrix	   metalloproteinases-­‐13	   (MMP-­‐13)	   and	   their	   major	  endogenous	   inhibitor,	   tissue	   inhibitor	   of	   metalloproteinases-­‐1	   (TIMP-­‐1),	   is	   also	   an	  important	   determinant	   of	   fibrosis	   progression.	   IFNγ-­‐PEG-­‐PPB	   induced	   a	   significant	  increase	  of	  the	  MMP-­‐13/TIMP-­‐1	  transcript	  ratio	  (p<0.01),	  suggesting	  fibrolytic	  activation	  (Fig.	  4C).	  As	  the	  IFNγ-­‐PEG-­‐PPB	  construct	  was	  found	  to	  be	  the	  most	  effective,	  it	  was	  further	  investigated	  in	  an	  established	  CCl4-­‐induced	  liver	  fibrosis	  model.	  
Figure	  3.	  HSC-­‐specific	  delivery	  IFNγ 	  conjugates	  in	  the	  acute	  CCl4-­‐induced	  liver	  injury	  model	  in	  
mice.	   (A)	   Representative	   immunofluorescent	   images	   showing	  HSC-­‐specific	   accumulation	   of	   IFNγ-­‐PPB	  and	   IFNγ-­‐PEG-­‐PPB	   in	   the	  damaged	  areas	   in	   livers	  while	   staining	  was	  absent	   in	  non-­‐damaged	  areas	   as	   indicated	  by	   arrows	   (n=6	  per	   group).	   PPB	  was	   visualized	  with	   a	   specific	   antibody	   (red);	  HSC	   with	   anti-­‐desmin	   IgG	   (green)	   and	   nuclei	   by	   counterstaining	   with	   DAPI	   (blue).	   400x	  magnification	   and	   further	   enlargement	   in	   the	   inserts.	  Representative	   photomicrographs	   (B)	   and	  quantitative	   image	   analysis	   (C)	   of	   MHC-­‐II-­‐stained	   liver	   sections	   of	   acutely	   CCl4-­‐treated	   mice	  following	   treatment	   with	   IFNγ	   or	   IFNγ	   constructs.	   Scale	   bars,	   200µm.	   IFNγ-­‐PEG-­‐PPB	   conjugate	  induced	   significant	   up-­‐regulation	   of	   MHC-­‐II	   expression	   in	   livers	   relative	   to	   all	   other	   groups.	   (D)	  Staining	  for	  MHC-­‐II	  (red),	  desmin	  (green)	  and	  nuclei	  (blue)	  showing	  enhanced	  expression	  of	  MHC-­‐II	  in	  HSC-­‐containing	  damaged	   areas.	  Original	  magnification,	   200x.	  #p<0.05	   versus	  PBS-­‐treated	  olive	  oil	  (normal)	  group;	  **p<0.01	  versus	  PBS-­‐treated	  CCl4	  animals.	  Bars	  represent	  mean	  ±	  SEM	  of	  6	  mice	  per	  group.	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3.6.	  Resolution	  of	  liver	  fibrosis	  by	  IFNγ-­‐PEG-­‐PPB	  in	  advanced	  CCl4-­‐induced	  fibrosis	  	  Mice	  received	  CCl4	  for	  8	  weeks	  to	  induce	  advanced	  liver	  fibrosis/cirrhosis.	  During	  the	  last	   2	   weeks,	   6	   doses	   of	   IFNγ	   or	   IFNγ-­‐conjugate	   (2.5	   µg/dose/mouse)	   or	   PBS	   were	  administered	   intravenously	  (Figure	  5A).	  Control	  CCl4	  mice	  developed	  extensive	  bridging	  fibrosis,	  substantial	  deposition	  of	  collagen	  and	  increased	  expression	  of	  the	  HSC	  markers	  α-­‐SMA	  and	  desmin	  (Figure	  5B).	  ALT	  and	  AST	   levels	  were	  strongly	  upregulated	   in	  all	  CCl4-­‐treated	   animals.	   Treatment	   with	   IFNγ,	   IFNγ-­‐PEG	   or	   IFNγ-­‐PEG-­‐PPB	   induced	   a	   20-­‐30%	  reduction	   in	   these	   levels	   (p<	   0.05,	  Supplementary	   Figure	   4).	   However,	   only	   treatment	  with	   IFNγ-­‐PEG-­‐PPB	   significantly	   inhibited	   bridging	   and	   reduced	   stainable	   collagen	   I	   by	  >70%	   (p<0.001),	   accompanied	  by	   a	   substantial	   reduction	   in	  α-­‐SMA	  and	  desmin-­‐positive	  HSC	   and	   relative	   hydroxyproline	   content	   (Figure	   5B-­‐5D).	   These	   reductions	   were	  paralleled	  by	  a	  significant	  decrease	  in	  respective	  transcript	  levels	  (Figure	  5E).	  Untargeted	  IFNγ	   (IFNγ	   and	   IFNγ-­‐PEG)	  only	   induced	  a	  moderate	  decrease	   in	   collagen	  expression	  and	  there	   was	   no	   significant	   decrease	   in	   the	   HSC	   activation	   markers	   α-­‐SMA	   and	   desmin,	  indicating	   that	   only	   IFNγ-­‐PEG-­‐PPB	   specifically	   affected	   fibrogenic	   HSC	   activation	   and	  proliferation	  (Figure	  5B-­‐5E).	  The	  reduction	  in	  desmin-­‐positive	  HSC	  was	  due	  to	  decreased	  
Figure	   4.	   Effects	   of	   targeted-­‐IFNγ 	   on	   fibrosis-­‐related	   parameters	   in	   the	   acute	   CCl4-­‐induced	  
model	  in	  mice.	  Representative	  pictures	  (A)	  and	  quantitative	  analysis	  (B)	  of	  collagen	  I	  and	  α-­‐SMA	  stained	   liver	  sections	   from	  CCl4-­‐treated	  mice	   (acute	  model)	   that	   received	   IFNγ	  or	   IFNγ	   constructs.	  Scale	   bars,	   200µm.	   For	   quantitative	   analysis,	   the	   groups	   were	   normalized	   to	   vehicle	   group	   (PBS	  treated-­‐CCl4	  mice).	   IFNγ-­‐PEG-­‐PPB	  induced	  a	  dramatic	  reduction	  in	  collagen	  I	  expression	  (*p<0.05)	  and	   α-­‐SMA	   expression	   (**p<0.01).	   #p<0.05	   denotes	   significance	   versus	   PBS-­‐treated	   olive	   oil	  (normal)	  group.	  (C)	  Effect	  of	  IFNγ	  constructs	  on	  fibrolytic	  activation	  as	  determined	  by	  the	  ratio	  of	  MMP13	  and	  TIMP-­‐1	   transcripts.	   (#p<0.05	   compared	   to	  PBS-­‐treated	  CCl4	   animals).	  Bars	   represent	  mean	  ±	  SEM	  of	  6	  mice	  per	  group.	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proliferation	  but	  not	  due	  to	  killing	  of	  the	  cells	  as	  confirmed	  by	  absence	  of	  apoptotic	  cells	  using	  caspase	  staining	  (data	  not	  shown),	  while	  significant	  reduction	  in	  proliferating	  nuclei	  (stained	  with	  Ki67	  antibody)	  was	  observed	  with	  targeted	  IFNγ	  construct	  (Supplementary	  
Figure	  5).	  	  
Figure	   5.	   Effects	   of	   targeted-­‐IFNγ 	   on	   fibrosis	   related	   parameters	   in	   CCl4-­‐treated	   cirrhotic	  
mice.	   (A)	  Regimen	  of	   liver	   fibrosis	   induction.	  After	  6	  weeks	  of	  CCl4	   injections,	  animals	   received	  IFNγ,	   IFNγ-­‐PEG,	   IFNγ-­‐PEG-­‐PPB	   (2.5	   µg/mice,	   3	   times	   a	   week)	   or	   PBS	   alone	   (n=6	   per	   group)	  intravenously	   for	   2	   weeks	   while	   CCl4	   injections	   were	   continued.	   (B)	   Representative	  photomicrographs	  and	  (C)	  computerized	  quantitative	  analysis	  of	  collagen	  I,	  α-­‐SMA-­‐	  and	  desmin-­‐stained	  liver	  sections	  of	  olive	  oil	  treated	  animals	  (normal)	  and	  fibrotic	  animals	  treated	  with	  PBS,	  IFNγ	  or	  modified	  IFNγ.	  Scale	  bars,	  200µm.	  For	  quantitative	  analysis,	  the	  groups	  were	  normalized	  to	   vehicle	   group	   (PBS	   treated-­‐CCl4	   mice).	   (D)	   Relative	   hepatic	   hydroxyproline	   content.	   (E)	  Quantitative	  real-­‐time	  PCR	  analysis	  of	  procollagen	  α1(I),	  α-­‐SMA,	  desmin,	  MMP13/TIMP-­‐1	  and,	  (F)	  SDF1α	   and	   CXCR4	   in	   olive	   oil-­‐treated	   mice	   (normal)	   and	   CCl4-­‐animals	   treated	   with	   PBS,	   IFNγ,	  IFNγ-­‐PEG,	  IFNγ-­‐PEG-­‐PPB.	  Expression	  levels	  were	  normalized	  with	  GAPDH.	  Bars	  represent	  mean	  ±	  SEM	   of	   6	   mice	   per	   group.	   #p<0.05	   versus	   olive	   oil;	   *p<0.05,	   **p<0.01	   versus	   PBS	   treated-­‐CCl4	  mice.	  These	  data	  shows	  reduction	  in	  fibrotic	  parameters	  with	  targeted-­‐IFNγ	  construct	  containing	  the	  PEG	  spacer	  and	  PDGFβ-­‐receptor	  homing	  peptide	  PPB	  (IFNγ-­‐PEG-­‐PPB),	  while	  native	  IFNγ	  and	  IFNγ-­‐PEG	  showed	  limited	  effectivity.	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In	  addition,	  the	  HSC-­‐targeted	  conjugate	  but	  not	  IFNγ	  and	  IFNγ-­‐PEG	  significantly	  enhanced	  the	  MMP-­‐13/TIMP-­‐1	  transcript	  ratio	  implying	  activation	  of	  fibrolysis	  (Figure	  5E).	  Finally,	  the	   chemokine	   receptor	   CXCR4	   and	   its	   ligand	   CXCL12/SDF1α	   which	   were	   recently	  implicated	   in	   HSC	   activation	   (24),	   were	   significantly	   down-­‐regulated	   by	   IFNγ-­‐PEG-­‐PPB	  (Figure	  5F),	  whereas	  IFNγ	  and	  IFNγ-­‐PEG	  had	  no	  effect.  
3.7.	   IFNγ-­‐PEG-­‐PPB	   inhibits	   angiogenesis	   and	   liver	   inflammation	   in	   chronic	   CCl4-­‐
induced	  liver	  fibrosis	  Angiogenesis	   that	   is	   induced	   by	   hypoxia	   within	   an	   injured	   liver	   and	   appears	   to	  aggravate	  hepatic	   fibrogenesis	   (25).	  Accordingly,	  using	  CD31	   immuno-­‐staining	  we	  noted	  significant	   neo-­‐vascularization	  which	  was	  paralleled	   by	   an	   increased	   angiopoietin-­‐1	   and	  
Figure	  6.	  Effect	  of	  targeted-­‐IFNγ 	  on	  angiogenesis	  and	  liver	  inflammation	  in	  CCl4	  fibrotic	  mice.	  (A)	   Representative	   photomicrographs	   of	   sections	   stained	   for	   CD31,	   angiopoietin-­‐1	   and	   fibronectin	  from	  olive	  oil-­‐treated	  mice	   (normal)	  and	  advanced	   fibrotic	  mice	   treated	  with	   IFNγ,	   IFNγ-­‐PEG,	   IFNγ-­‐PEG-­‐PPB	  or	  PBS	  alone	  (n=6).	  Scale	  bars,	  200µm.	  (B)	  Quantitative	  real-­‐time	  PCR	  analysis	  of	  CD31	  and	  angiopoietin1	  mRNA	  expression,	  normalized	  with	  GAPDH.	  #p<0.05	  versus	  olive	  oil;	  *p<0.05,	  **p<0.01	  versus	  PBS	   treated-­‐CCl4	  mice.	  Results	   show	  significant	   inhibition	  of	   angiogenesis	  by	   IFNγ-­‐PEG-­‐PPB.	  
(C)	   Representative	   photomicrographs	   showing	   liver	   sections	   stained	   for	   the	   macrophage	   marker	  F4/80.	   The	   pictures	   show	   effective	   inhibition	   of	   liver	   inflammation	   with	   HSC-­‐specific	   targeting	   of	  IFNγ.	   (D)	  Transcripts	   levels	   for	   CD68,	   F4/80	   and	  MIP-­‐2.	   Significant	   reduction	   of	   CD68,	   F4/80	   and	  MIP-­‐2	  transcripts	  with	  IFNγ-­‐PEG-­‐PPB	  was	  observed.	  Bars	  represent	  mean	  ±	  SEM	  of	  6	  mice	  per	  group.	  #p<0.05	  versus	  PBS-­‐treated	  olive	  oil	  group;	  *p<0.05,	  **p<0.01	  versus	  PBS	  treated-­‐CCl4	  group.	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fibronectin	   expression	   (26,	   27)	   in	   livers	   of	  mice	   chronically	   treated	  with	   CCl4.	   All	   these	  parameters	  were	  ameliorated	  by	  IFNγ	  and	  IFNγ-­‐PEG	  treatment,	  but	  most	  dramatically	  by	  IFNγ-­‐PEG-­‐PPB	   (Figure	   6A,	   6B).	   Since	   PDGF	   receptor	   blockade	   can	   also	   lead	   to	   anti-­‐angiogenic	  effects	  we	  administered	  higher	  doses	  of	  PPB	  coupled	  to	  a	  non-­‐bioactive	  protein	  (albumin)	   and	   did	   not	   observe	   any	   reduction	   in	   CD31	   staining	   in	   chronic	   CCl4	   model	  (Supplementary	  Figure	  6).	  Liver	  fibrosis	  is	  also	  an	  inflammation-­‐driven	  process	  (28)	  and	  HSC	  can	  modulate	  the	  recruitment	   of	   inflammatory	   cells	   during	   fibrogenesis	   (5).	   Compared	   to	   PBS,	   IFNγ	   and	  IFNγ-­‐PEG,	   IFNγ-­‐PEG-­‐PPB	   showed	   a	   significant	   decrease	   in	   MIP2	   (macrophage	  inflammatory	  protein	  2)	  expression	  and	  lower	  numbers	  of	  macrophages	  as	  evidenced	  by	  staining	  for	  F4/80,	  and	  CD68	  and	  F4/80	  RNA	  transcript	  levels	  (Figure	  6C,	  6D).	  Additional	  effects	   on	   other	   inflammatory	   cells	   (neutrophils,	   CD4,	   CD8	   and	   dendritic	   cells)	   were	  investigated	   but	   no	  significant	  differences	  were	  observed	   (Supplementary	  
Figure	  7).	  
Reduction	  in	  IFNγ-­‐related	  
side	   effects	   with	   IFNγ-­‐
PEG-­‐PPB	  conjugate	  	  Main	   hurdles	   in	   IFNγ-­‐based	   therapies	   are	   the	  adverse	   effects	   due	   to	   the	  pro-­‐inflammatory	   activity	  of	   IFNγ,	   one	   reason	   for	   its	  failures	  in	  clinical	  trials.	  To	  investigate	   whether	  targeting	   of	   IFNγ	   could	  ameliorate	   these	   IFNγ-­‐
Figure	  7.	  Effect	  of	   targeted-­‐IFNγ 	  on	  IFNγ-­‐related	  side	  effects	   in	  CCl4-­‐fibrotic	  mice.	  Analysis	  of	  adverse	   effects	   after	   2	   weeks	   of	   treatment	   with	   PBS,	   IFNγ,	   IFNγ-­‐PEG	   or	   IFNγ-­‐PEG-­‐PPB	   (2.5	  
µg/mouse).	  (A)	  Rectal	  temperature	  of	  CCl4-­‐treated	  cirrhotic	  mice	  receiving	  PBS	  or	  the	  different	  IFNγ	  constructs.	   #p<0.05	   vs.	   PBS-­‐treated	   CCl4	   group,	   *p<0.05	   vs.	   IFNγ-­‐PEG	   treated	   group.	   (B	   and	   C)	  Plasma	  levels	  of	  TNF-­‐α	  and	  IL-­‐6	  in	  IFNγ-­‐	  and	  IFNγ-­‐construct	  treated	  cirrhotic	  mice.	  #p<0.05	  vs	  PBS-­‐treated	  CCl4	  group.	  (D)	  mRNA	  expression	  of	  eNOS	  in	  the	  livers	  from	  treated	  animals	  as	  analyzed	  by	  qRT-­‐PCR	   (normalized	   with	   GAPDH).	   #p<0.05	   vs.	   PBS-­‐treated	   CCl4	   group;	   *p<0.05	   vs.	   IFNγ-­‐PEG	  treated	   group.	   (E)	   Triglyceride	   levels	   in	   plasma	   of	   CCl4-­‐fibrotic	   mice	   treated	   with	   different	  compounds.	   #p<0.05	   represents	   significance	   versus	   PBS-­‐treated	   CCl4	   group;	   *p<0.05	   versus	   IFNγ	  treated	   group.	   (F)	   MHC-­‐II	   mRNA	   expression	   in	   brain	   tissue	   from	   PBS,	   IFNγ	   and	   IFNγ	   constructs	  treated	  cirrhotic	  mice	  as	  determined	  by	  qPCR.	  #p<0.05	  vs.	  PBS-­‐treated	  CCl4	  group;	  *p<0.05	  vs.	  IFNγ-­‐PEG	  treated	  group	  and	  **	  p<0.01	  vs.	  IFNγ	  treated	  group.	  Bars	  represent	  mean	  ±	  SEM	  of	  n=6	  mice	  per	  group.	  These	  data	  show	  that	  IFNγ	  and	  IFNγ-­‐PEG	  induce	  clinically	  relevant	  adverse	  effects	  but	  IFNγ-­‐PEG	  delivered	  through	  the	  homing	  peptide	  PPB	  is	  devoid	  of	  these	  side	  effects.	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mediated	  side	  effects,	  we	  focused	  on	  clinically	  relevant	  side	  effects	  such	  as	  fever,	  elevated	  plasma	   triglycerides,	   endothelial	   cell	   activation,	   pro-­‐inflammatory	   cytokine	   release	   and	  central	   nervous	   system	   (CNS)	   effects(29-­‐31).	   While	   IFNγ-­‐PEG	   treatment	   induced	   an	  significant	  rise	  in	  body	  temperature,	  endothelial	  cell	  activation	  (eNOS),	  plasma	  TNF-­‐α	  and	  IL-­‐6	   levels	   (Figure	   7A-­‐D),	   these	   side	   effects	  were	   completely	   absent	   in	   animals	   treated	  with	   HSC-­‐targeted	   IFNγ-­‐PEG-­‐PPB	   (Figure	   7A-­‐D).	   We	   also	   observed	   increased	   plasma	  triglycerides	   induced	   by	   IFNγ,	   which	   remained	   unaltered	   after	   IFNγ-­‐PEG-­‐PPB	   treatment	  (Figure	   7E).	   Neurotropic	   effects	  were	   analyzed	   by	   examining	   the	   expression	   of	  MHC-­‐II,	  the	  norepinephrine	  transporter	  (NET)	  and	  Indoleamine-­‐pyrrole	  2,	  3-­‐dioxygenase-­‐I	  (IDO-­‐I)	  in	  the	  brain.	  While	  IFNγ	  or	  IFNγ-­‐PEG	  induced	  significant	  up-­‐regulation	  of	  MHC-­‐II,	  NET	  and	  IDO-­‐I	  expression,	  these	  parameters	  were	  unchanged	  in	  the	  IFNγ-­‐PEG-­‐PPB	  treated	  animals	  (Figure	  7F	  and	  Supplementary	  Figure	  8).	  
4.	  DISCUSSION	  Liver	   cirrhosis	   is	   a	   slowly	   progressive	   process	   tightly	   controlled	   by	   endogenous	  mediators.	  While	   certain	   local	  mediators	  might	  provide	  novel	   therapeutic	   opportunities,	  their	   systemic	  use	   is	   fraught	  with	   tremendous	  hurdles	   such	   as	   insufficient	   access	   to	   the	  fibrotic	  liver	  and	  adverse	  reactions,	  as	  is	  particularly	  true	  for	  IFNγ.	  To	  date,	  no	  proven	  anti-­‐fibrotic	   pharmacotherapy	   is	   available	   to	   inhibit	   the	   progression	   or	   induce	   regression	   of	  human	   liver	   fibrosis	   and	   cirrhosis.	   Our	   strategic	   approach	   was	   therefore	   to	   chemically	  engineer	   the	   IFNγ	   molecule	   to	   redirect	   it	   to	   the	   fibrogenic	   target	   cells,	   while	   avoiding	  undesired	  off-­‐target	  effects.	  We	  could	  show	  that	  specific	  targeting	  of	  IFNγ	  to	  activated	  HSC,	  key	   effector	   cells	   of	   liver	   fibrogenesis,	   increased	   its	   therapeutic	   efficacy	   but	   strikingly	  reduced	  unwanted	  side	  effects	  by	  avoiding	  its	  interaction	  with	  non-­‐target	  cells	  in	  the	  liver	  and	  other	  tissues.	  We	  used	  the	  PDGFβ	  receptor	  as	  the	  target	  receptor	  for	  delivery	  of	  IFNγ	  due	  to	  its	  specific	  and	  high	  induction	  on	  activated	  HSC	  during	  liver	  injury	  (15,	  16).	  To	  date,	  such	  approach	  has	  not	  been	  described.	  Due	   to	   their	   potency,	   cytokines	   have	   been	   the	   focus	   of	   several	   new	   biological	  therapeutics	   (32).	   However,	   only	   very	   few	   cytokines	   have	  made	   their	  way	   to	   the	   clinic,	  mainly	   due	   to	   their	   short	   half-­‐life	   and	   adverse	   side-­‐effects.	   Their	   plasma	   stability	   and	  circulation	   life-­‐span	  can	  be	   increased	  through	  PEGylation	  (e.g.	  PEGASYS	  and	  PEGIntron),	  liposomal	   encapsulation	   or	   coupling	   to	   carriers	   (33,	   34).	   However,	   although	   these	  approaches	   improved	   the	   biological’s	   half-­‐life,	   they	   still	   fail	   to	   prevent	   their	   interaction	  with	  non-­‐target	  cells	  and	  concomitant	  side	  effects.	  Here,	  we	  demonstrate	  for	  the	  first	  time	  that	  redirecting	  a	  cytokine	  from	  its	  ubiquitously	  expressed	  receptor	  to	  another	  target	  cell	  specific	  receptor	  (PDGFβR),	  can	  both	  lead	  to	  enhanced	  therapeutic	  efficiency	  and	  reduced	  side	  effects.	  PDGFβR	   is	   highly	   induced	   on	   activated	   HSC	   (and	   portal	   myofibroblasts)	   in	   rodent	  and	  human	  liver	  fibrogenesis	  but	  it	  is	  also	  expressed	  to	  a	  minor	  extent	  on	  vascular	  smooth	  muscle	  cells.	  Keeping	   in	  mind	  the	  hurdles	  of	  pharmacokinetics	  and	   in	  vivo	   instability,	  we	  designed	   different	   strategies	   to	   conjugate	   the	   cyclic	   PDGFβR-­‐binding	   peptide	   PPB	   to	  mouse	  IFNγ,	  using	  either	  direct	  coupling	  (IFNγ-­‐PPB)	  or	  via	  a	  PEG	  linker	  (IFNγ-­‐PEG-­‐PPB),	  in	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order	   to	   provide	   hydrophilicity,	   stability	   and	   conformational	   flexibility	   for	   appropriate	  receptor	  interaction.	  Modification	  of	  cytokines	  is	  always	  a	  challenging	  task	  as	  this	  can	  result	  in	  a	  complete	  or	  partial	  loss	  of	  biological	  activity	  (35).	  However,	  using	  mild	  conditions	  during	  synthesis,	  PPB-­‐modified	  IFNγ	  constructs	  completely	  retained	  their	  biological	  activity	  as	  analyzed	  in	  mouse	   RAW	  macrophages.	   PDGFβR-­‐specific	   binding	   was	   subsequently	   demonstrated	   in	  mouse	  fibroblasts,	  primary	  rat	  HSC	  and	  human	  hepatic	  stellate	  cell	  line	  LX2	  using	  specific	  antibodies.	  Moreover,	  while	  mouse-­‐derived	   IFNγ	  was	   only	   effective	   in	  murine	   cells,	   PPB	  containing	  IFNγ	  constructs	  were	  also	  effective	  in	  human	  cells,	  further	  demonstrating	  that	  the	  biological	  activity	  of	  IFNγ-­‐PEG-­‐PPB	  is	  mediated	  through	  PDGFβ	  receptor.	  It	   is	   known	   that	   IFNγ	   has	   a	   receptor	   binding	   sequence	   and	   a	   nuclear	   signaling	  sequence	   (NLS)	   which	   mediates	   its	   biological	   effects	   (36).	   IFNγ-­‐mediated	   effects	   occur	  through	  intracellular	  uptake	  of	  the	  nuclear	  signaling	  sequence,	  which	  subsequently	  binds	  to	   its	   intracellular	   target	   through	   JAK-­‐STAT	   pathway	   and	   modulates	   IFNγ-­‐responsive	  genes.	   While	   our	   construct	   is	   taken	   up	   via	   the	   PDGFR,	   the	   internalized	   construct	   is	  apparently	   able	   to	   bind	   to	   its	   intracellular	   target.	  Most	   likely,	   the	   internalized	   construct	  releases	   IFNγ	   or	   its	   metabolite	   intracellularly	   but	   this	   needs	   to	   be	   further	   explored.	   Of	  note,	   to	   test	   whether	   the	   anti-­‐fibrotic	   and	   anti-­‐angiogenic	   effects	   were	   not	   due	   to	   a	  blockade	  of	  the	  PDGFβR	  induced	  by	  PPB,	  we	  coupled	  PPB	  to	  human	  serum	  albumin	  (PPB-­‐HSA)	  and	  no	  significant	  effects	  were	  observed	  in	  vitro	  and	  in	  vivo.	  Our	   targeted-­‐IFNγ	   constructs	   quite	   rapidly	   accumulated	   in	   HSC	   and	   HSC-­‐specific	  accumulation	   was	   confirmed	   also	   by	   local	   up-­‐regulation	   of	   MHC-­‐II	   expression,	   a	   well-­‐known	  activity	  of	  IFNγ	  (23).	  In	  these	  experiments,	  we	  found	  that	  IFNγ-­‐PEG-­‐PPB	  was	  more	  potent	  than	  IFNγ-­‐PPB,	  illustrating	  the	  relevance	  of	  the	  PEG	  linker.	  Furthermore,	  improved	  anti-­‐fibrotic	  effect	  of	   targeted-­‐IFNγ	  constructs	  such	  as	  reduction	  of	  α-­‐SMA	  and	  collagen	  I	  expression	   and	   significant	   increase	   of	   the	   MMP-­‐13/TIMP-­‐1	   ratio	   demonstrated	   the	  rationale	   and	   efficiency	   of	   cell-­‐specific	   targeting.	   In	   all	   experimental	   settings,	   IFNγ-­‐PEG-­‐PPB	  induced	  the	  most	  prominent	  anti-­‐fibrotic	  effects.	  Advanced	   liver	   fibrosis/cirrhosis	   develops	   during	   many	   years	   in	   patients	   with	  chronic	  liver	  disease	  and	  to	  induce	  regression	  of	  fibrosis	  represents	  a	  major	  challenge.	  In	  our	  study,	  we	  induced	  advanced	  liver	  cirrhosis	  in	  mice	  by	  chronic	  treatment	  with	  CCl4	  for	  6	  weeks	  and	  then	  examined	  the	  therapeutic	  efficacy	  of	  the	  targeting	  construct	  for	  another	  2	   weeks,	   while	   continuing	   the	   CCl4	   injections	  mimicking	   the	   ongoing	   liver	   damage	   that	  occurs	   in	   humans.	   IFNγ-­‐PEG-­‐PPB	   treatment	   strikingly	   diminished	   fibrosis	   by	   a	   strong	  inhibition	   of	   HSC	   activation	   and	   proliferation,	   a	   significant	   reduction	   in	   collagen	  deposition	   and	   an	   increase	   in	   the	  MMP-­‐13/TIMP-­‐1	   ratio,	   whereas	   untargeted	   IFNγ	   was	  only	  modestly	  effective	  (non-­‐significant)	  due	  to	  the	  relatively	  low	  dose	  used	  in	  the	  present	  study	  (2.5	  µg/dose/mice)	  compared	  to	  other	  studies	  (5	  µg/dose/mice)	  (37).	  	  Recent	   reports	   highlight	   the	   relevance	   of	   angiogenesis	   in	   the	   pathogenesis	   of	   liver	  fibrosis	   (25-­‐27)	   whereas	   the	   role	   of	   chronic	   inflammation	   has	   been	   recognized	   earlier	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(28).	   The	   significant	   inhibition	   of	   these	   processes	   by	   the	   targeted	   construct	   and	   not	   by	  native	  IFNγ,	  further	  highlights	  the	  potency	  of	  our	  targeting	  approach.	  	  Adverse	  effects	  have	  been	  the	  main	  reason	  for	  patient	  withdrawal	  from	  clinical	  trials	  with	   IFNγ.	   IFNγ	   is	   a	   very	   potent	   pro-­‐inflammatory	   cytokine	   with	   a	   ubiquitous	   receptor	  expression,	   and	   therefore	   IFNγ-­‐based	   experimental	   therapies	   are	   associated	   with	   side	  effects	   like	   severe	   flu-­‐like	   symptoms,	   systemic	   endothelial	   and	   immune	   cell	   activation,	  neurotropic	  effects	  and	  hyperlipidemia.	  In	  our	  study,	  we	  observed	  that	  both	  free	  IFNγ	  and	  PEGylated	  IFNγ	  induced	  hyperthermia,	  elevated	  plasma	  triglyceride	  levels,	  endothelial	  cell	  activation,	   serum	   TNF-­‐α	   and	   IL-­‐6	   levels,	   and	   CNS	   inflammation.	   Notably,	   these	   adverse	  reactions	  were	  completely	  absent	  following	  IFNγ-­‐PEG-­‐PPB	  administration.	  	  In	  conclusion,	  we	  report	  here	  a	  novel	  approach	  of	  chemically	  engineering	  a	  cytokine	  to	  shift	  its	  receptor	  specificity	  by	  directing	  it	  to	  the	  myofibroblast-­‐like	  cells	  (activated	  HSC)	  in	   liver.	   Using	   this	   approach,	   targeting	   of	   IFNγ	   ameliorated	   advanced	   liver	   fibrosis	   and	  eliminated	   the	   IFNγ-­‐related	   adverse	   effects.	   We	   believe	   that	   this	   illustrates	   new	  opportunities	  to	  utilize	  cytokines	  more	  effectively	  for	  the	  therapy	  of	  hepatic	  fibrosis.	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  Supplementary	  Table	  1:	  Primary	  antibodies	  used	  for	  the	  immuno-­‐histology	  
	  
Antibody	   Source	   Dilution	  Polyclonal	  goat	  anti-­‐angiopoietin1	   Alpha	  diagnostics	   1:200	  Monoclonal	  mouse	  anti-­‐α-­‐SMA	  	   Sigma	   1:600	  Polyclonal	  rat	  anti-­‐CD31	  	   BD	  Pharmingen	   1:200	  Polyclonal	  goat	  anti-­‐collagen	  I	   Southern	  Biotech	   1:100	  Polyclonal	  goat	  anti-­‐collagen	  III	  	   Southern	  Biotech	   1:100	  Polyclonal	  goat	  anti-­‐desmin	   Santa	  Cruz	   1:100	  Monoclonal	  mouse	  anti-­‐fibronectin	   Sigma	   1:200	  Polyclonal	  rat	  anti-­‐F4/80	  (MCA497)	  	   AbD	  Serotec	   1:500	  Polyclonal	  rabbit	  anti-­‐IFNγ	   Abcam	   1:100	  Polyclonal	  rabbit	  anti-­‐Ki67	  antibody	   Abcam	   1:250	  Monoclonal	  rat	  anti-­‐MHC	  II	  (ER-­‐TR3)	   Santa	  Cruz	   1:400	  Monoclonal	  rat	  anti-­‐neutrophils	  (NIMP)	   Abcam	   1:500	  Monoclonal	  rabbit	  anti-­‐PDGFβR	   Cell	  signaling	   1:100	  Polyclonal	  rabbit	  anti-­‐PPB	   Custom-­‐made	  by	  Harlan	   1:100	  
50	   [CHAPTER	  3]	  
 
 
Supplementary	  Table	  2:	  Sequence	  of	  the	  primers	  used	  for	  quantitative	  real-­‐time	  
PCR	  
	  
Abbreviations:	   18s	   rRNA,	   18s	   ribosomal	   RNA;	   PDGFβR,	   Platelet-­‐derived	   growth	   factor	   receptor	  beta;	  CD31,	  Cluster	  of	  Differentiation	  31;	  CD68,	  Cluster	  of	  Differentiation	  68;	  CXCR4,	  CXC	  chemokine	  receptor	  4;	  F4/80	  or	  EMR1,	  EGF-­‐like	  module-­‐containing	  mucin-­‐like	  hormone	  receptor-­‐like	  1;	  GAPDH,	  Glyceraldehyde	   3-­‐phosphate	   dehydrogenase;	   IDO-­‐I,	   Indoleaminepyrrole	   2,3-­‐dioxygenase	   I;	  MHC-­‐II,	  major	   histocompatibility	   complex	   Class	   II;	   MIP-­‐2,	   macrophage	   inflammatory	   protein	   2;	   MMP-­‐13,	  matrix	   metalloproteinase	   13;	   NET,	   Norepinephrine	   transporter;	   eNOS	   or	   NOS3,	   endothelial	   nitric	  oxide	   synthase	   3;	   SDF1α,	   	   stromal	   cell-­‐derived	   factor-­‐1	   alpha;	  α-­‐sma,	   alpha-­‐smooth	  muscle	   actin;	  TIMP-­‐1,	  Tissue	  inhibitor	  of	  metalloproteinases.	  	  
Gene	   Forward	   Reverse	  
Human	   	   	  18s	  rRNA	   CGGCTACCCACATCCAAGGA	   CCAATTACAGGGCCTCGAAA	  PDGFβR	   CATGGGGGTATGGTTTTGTC	   GTAAGGTGCCAACCTGCAAT	  
Mouse	   	   	  Angiopoeitin	  1	   GCAGCAACCAGCGCCGAAAT	   CACGGCAGTTCCCGTCGTGT	  CD31	   TCCCTGGGAGGTCGTCCAT	   GAACAAGGCAGCGGGGTTTA	  CD68	   TACGACCAGCCACAGGCCCA	   TCCAGGGTGAGGGCCAACAG	  Collagen	  I	   TGACTGGAAGAGCGGAGAGT	   ATCCATCGGTCATGCTCTCT	  CXCR4	   TGCCTTCCTCGGGGCCAAGT	   CGGAAGAGTGTCCACCCCGC	  Desmin	   ATGCAGCCACTCTAGCTCGT	   CTCATACTGAGCCCGGATGT	  F4/80	   GCCCAGCTTATGCCACCTGC	   GCTGCACTTGGCTCTCCCCA	  GAPDH	  	   ACAGTCCATGCCATCACTGC	   GATCCACGACGGACACATTG	  IDO-­‐I	  	   AAGGGCTTCTTCCTCGTCTC	   AAAAACGTGTCTGGGTCCAC	  MHC-­‐II	   TCCAGATGCCAACGTGGCCC	   TGCGGAAGAGGTGATCGTCCC	  MIP-­‐2	   TCCAGAGCTTGAGTGTGACG	   CTTTGGTTCTTCCGTTGAGG	  MMP-­‐13	   CCAGAACTTCCCAACCATGT	   GTCTTCCCCGTGTTCTCAAA	  NET	  (SLC6A2)	   GTGGCAAAGTTGGCTCCTGA	   ACCTTCGTGAGACCCTCCAG	  NOS3	  or	  eNOS	   CGATGTCACTATGGCAACCA	   CCTGCAAAGAAAAGCTCTGG	  PDGFβR	   AACCCCCTTACAGCTGTCCT	   TTCCTCTCATTGCCCATCTC	  SDF1α	   CAGAGCCAACGTCAAGCA	   AGGTACTCTTGGATCCAC	  α-­‐sma	   ACTACTGCCGAGCGTGAGAT	   CCAATGAAAGATGGCTGGAA	  TIMP-­‐1	   ATCAGTGCCTGCAGCTTCTT	   TGACGGCTCTGGTAGTCCTC	  




















































































Supplementary	  Figure	  1.	  Synthesis	  of	  Interferon	  gamma	  conjugates.	  PDGFβR-­‐recognizing	  peptide	  was	   either	   directly	   coupled	   to	   IFNγ	   using	   the	   GMBS	   linker	   to	   generate	   IFNγ-­‐PPB	   (a)	   or	   indirectly	  coupled	  via	  a	  bi-­‐functional	  PEG	   linker	   to	   synthesize	   IFNγ-­‐PEG-­‐PPB	   (b).	   IFNγ-­‐PEG	  was	   synthesized	  by	  direct	  conjugation	  of	  a	  mono-­‐functional	  PEG	  linker	  to	  IFNγ	  (c). 
Supplementary	  Figure	  2.	  Characterization	  of	  IFNγ 	  conjugates.	  Western	  blot	  analysis	  was	  used	  to	  characterize	  IFNγ	  conjugates	  using	  an	  anti-­‐IFNγ	  antibody	  (a)	  and	  an	  anti-­‐PPB	  antibody	  (b).	  M	  denotes	  molecular	  weight	  markers;	  Lane	  I:	  unmodified	  IFNγ,	  Lane	  II:	  IFNγ-­‐PPB	  conjugate;	  Lane	  III:	  IFNγ-­‐PEG-­‐PPB	  conjugate;	  Lane	   IV:	   IFNγ-­‐PEG	  conjugate.	  The	   shift	   in	   the	  bands	  of	   IFNγ	  monomers	  and	  dimers	  after	   conjugation	   and	   the	   superimposable	   pattern	   after	   incubation	   with	   the	   anti-­‐PPB	   antibody	  indicates	  successful	  coupling	  and	  complete	  modification. 
52	   [CHAPTER	  3]	  
 
 











Supplementary	  Figure	  3.	  In	  vitro	  PDGFβR-­‐specific	  binding	  IFNγ 	  and	  targeted-­‐IFNγ 	  conjugates	  
in	  primary	  rat	  hepatic	  stellate	  cells.	  Photographs	  showing	  binding	  of	  IFNγ-­‐PPB	  or	  IFNγ-­‐PEG-­‐PPB	  to	   freshly	   isolated	   primary	   rat	   HSC.	   The	   cells	   were	   stained	   for	   anti-­‐IFNγ	   and	   anti-­‐PPB	   antibody.	  Mouse	  IFNγ	  did	  not	  show	  any	  binding	  to	  rat	  HSC	  due	  to	  species	  differences.	  	  
 
Supplementary	  Figure	  4:	  Significant	  reduction	  in	  liver	  enzymes	  (Aspartate	  aminotransferases	  (AST)	  and	  Alanine	  aminotransferases	  (ALT)	  were	  observed	   in	   IFNγ-­‐,	   IFNγ-­‐PEG-­‐	  and	  IFNγ-­‐PEG-­‐PPB-­‐treated	  chronic	  CCl4	  fibrotic	  animals	  as	  compared	  to	  CCl4	  fibrotic	  animals	  treated	  with	  PBS.	  ##P<0.05	  vs.	  PBS	  treated	  olive	  oil	  group;	  *	  P<0.05	  and	  **P<0.01	  vs.	  PBS	  treated	  CCl4	  group.	  Bars	  represent	  mean	  ±	  SEM	  (n=6	  mice	  per	  group).	  	  
 
Supplementary	  Figure	  5:	  Effect	  
of	   targeted-­‐IFNγ 	   on	   HSC	  
proliferation	   in	   CCl4	   fibrotic	  
mice.	   Representative	  photomicrographs	   of	   sections	  stained	   with	   Ki67	   antibody	   from	  olive	   oil-­‐treated	   mice	   (control)	  and	   advanced	   fibrotic	   mice	  treated	   with	   IFNγ,	   IFNγ-­‐PEG,	  IFNγ-­‐PEG-­‐PPB	   or	   PBS	   alone	  (n=6).	   Results	   show	   significant	  reduction	  in	  HSC	  and	  hepatocytes	  proliferation	  by	  IFNγ-­‐PEG-­‐PPB.	  
 






Supplementary	   Figure	   6:	  
Effect	   of	   PPB-­‐HSA	   on	  
angiogenesis	   in	   CCl4	   fibrotic	  
mice.	   Representative	  photomicrographs	   of	   sections	  stained	   with	   CD31	   antibody	  from	  CCl4-­‐induced	   fibrotic	  mice	  treated	  with	  either	  PBS	  or	  PPB-­‐HSA	   (n=6).	   No	   effect	   on	  angiogenesis	  was	  observed	  with	  PPB-­‐HSA	   administration	  confirming	   no	   effect	   of	   PDGF	  receptor	  blockade.	  
 
Supplementary	   Figure	   7:	   Effect	   on	   neutrophil	   infiltration	   in	  livers	   from	   PBS,	   IFNγ,	   IFNγ-­‐PEG	   or	   IFNγ-­‐PEG-­‐PPB	   treated	  chronic	   CCl4	   fibrotic	   animals	   as	   compared	   to	   olive	   oil	   treated	  normal	   animals.	   #P<0.05	   vs.	   PBS	   treated	   olive	   oil	   group.	   Bars	  represent	  mean	  ±	  SEM	  (n=6	  mice	  per	  group).	  	  
 
Supplementary	   Figure	   8:	   Significant	  upregulation	   of	   norepinephrine	  transporter	   (NET)	   and	   indoleamine-­‐pyrrole	   2,3-­‐dioxygenase	   I	   (IDO	   I)	  transcripts	   in	   brain	   tissues	   from	   IFNγ	  treated	  chronic	  CCl4	  fibrotic	  animals	  as	  compared	   to	   either	   olive	   oil	   treated	  normal	   animals	   or	   CCl4	   fibrotic	  animals	  treated	  with	  PBS,	  IFNγ-­‐PEG	  or	  IFNγ-­‐PEG-­‐PPB.	   #P<0.05	   vs.	   PBS	  treated	   CCl4	   group;	   *	   P<0.05	   vs.	   IFNγ	  treated	   group.	   Bars	   represent	  mean	  ±	  SEM	  (n=6	  mice	  per	  group).	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SUPPLEMENTARY	  MATERIALS	  AND	  METHODS	  
S.1.	  Synthesis	  of	  Interferon	  gamma	  conjugates	  IFNγ-­‐PPB	  conjugate:	  0.256	  nmol	  murine	   IFNγ	   (Peprotech,	  London,	  UK)	  was	  reacted	  with	  6.4	  nmol	  of	  N-­‐[γ-­‐maleimidobutyryloxy]	  succinimide	  ester	  (GMBS;	  Sigma,	  St.	  Louis,	  MO)	  for	  2	  hrs	  and	  purified	  by	  dialysis	  using	  Zeba	  spin	  columns	  (Pierce	  biotechnology).	  The	  purified	  product	  was	  reacted	  overnight	  with	  PPB-­‐ATA	  (25.6	  nmol)	  in	  the	  presence	  of	  deacetylating	  reagent	   (0.1	  M	   hydroxylamine,	   25mM	   EDTA	   in	   PBS	   pH	   7.2).	   PPB-­‐ATA,	   an	   8-­‐amino-­‐acid	  cyclic	   peptide	  modified	  with	   SATA,	  was	   synthesized	  by	  Ansynth	   Service	  B.V	   (Rosendaal,	  The	   Netherlands)	   as	   described	   elsewhere	   (1;2).	   The	   prepared	   IFNγ-­‐PPB	   conjugate	   was	  extensively	   dialyzed	   against	   PBS	   using	   a	   10	   KDa	   dispodialyzer	   (Harvard	   Apparatus,	  Holliston,	  Massachusetts).	  	  IFNγ-­‐PEG-­‐PPB	   conjugate:	   IFNγ	   (0.256	   nmol)	   was	   reacted	   with	   12.8	   nmol	   of	   maleimide-­‐PEG-­‐succinimidyl	   carboxy	   methyl	   ester	   (Mal-­‐PEG-­‐SCM,	   2	   KDa,	   Creative	   PEGworks,	  Winston	   Salem,	   NC)	   for	   2	   hrs	   and	   was	   dialyzed	   overnight.	   The	   purified	   product	   was	  further	   reacted	   with	   PPB-­‐ATA	   (25.6	   nmol)	   in	   the	   presence	   of	   deacetylating	   reagent.	  Finally,	  IFNγ-­‐PEG-­‐PPB	  was	  extensively	  dialyzed	  against	  PBS.	  IFNγ-­‐PEG	   conjugate:	   IFNγ	   (0.256	   nmol)	   was	   reacted	   with	   12.8	   nmol	   of	   Poly	   (ethylene	  glycol)-­‐succinimidyl	   α-­‐methylbutanoate	   (mPEG-­‐SMB,	   2	   KDa,	   Nektar	   therapeutics)	   for	   2	  hrs	  and	  subsequently	  the	  product	  was	  dialyzed	  extensively.	  
S.2.	  Characterization	  of	  IFNγ 	  conjugates	  by	  western	  blotting	  The	  IFNγ	  conjugates	  were	  characterized	  by	  western	  blotting	  using	  anti-­‐IFNγ	  and	  anti-­‐PPB	   antibodies.	   IFNγ	   conjugates	   were	   subjected	   to	   SDS-­‐PAGE	   (12%)	   and	   the	   separated	  proteins	  were	  transferred	  to	  PVDF	  membrane.	  The	  membranes	  were	  blocked	  with	  TBST	  (20	  mM	  TrisHCl,	  pH7.6,	  154	  mM	  NaCl,	  0.1%	  Tween20)	  containing	  5%	  skimmed	  milk	  and	  incubated	  with	  either	  rabbit	  polyclonal	   IFNγ	   antibody	  (Abcam,	  Cambridge,	  UK)	  or	  rabbit	  polyclonal	  PPB	  antibody	  (custom-­‐made,	  Harlan).	  After	  washings,	  the	  blots	  were	  incubated	  with	   HRP-­‐conjugated	   goat	   anti-­‐rabbit	   antibody	   (DAKO,	   Glostrup,	   Denmark).	   Finally,	   the	  blots	  were	   developed	   using	  Western	   Lightning-­‐ECL	   reagent	   (Perkin-­‐Elmer,	   Boston,	  MA)	  according	  to	  the	  manufacturer’s	  instructions.	  	  
S.3.	  Immunohistochemistry	  and	  immunofluorescence	  The	   cells	   were	   fixed	   with	   acetone:methanol	   (1:1),	   dried	   and	   stored	   until	  immunostaining.	   Livers	   and	  other	   tissues	  were	   cut	  with	   a	   cryostat	   (4µm	   thickness)	   and	  fixed	   in	   acetone.	   Cells	   or	   tissue	   sections	   were	   incubated	   with	   the	   primary	   antibody	  (antibodies	   are	   listed	   in	   Supplementary	   Table	   1).	   Subsequently,	   they	   were	   incubated	  with	   horseradish	   peroxidase-­‐	   or	   FITC-­‐/TRITC-­‐conjugated	   secondary	   antibodies.	  Peroxidase	   activity	   was	   developed	   with	   3-­‐amino-­‐9-­‐ethyl	   carbazole	   (Sigma)	   and	   nuclei	  were	  counterstained	  with	  hematoxylin	  (Fluka	  Chemie,	  Buchs,	  Switzerland).	  Mounted	  cells	  or	   sections	   were	   visualized	   using	   a	   light	   microscope	   (Olympus,	   Essex,	   UK).	   For	  immunofluorescence,	   cells	  or	   sections	  were	  counterstained	  with	  DAPI,	   citifluor-­‐mounted	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and	   examined	   with	   a	   fluorescence	   microscope	   (Leica,	   Cambridge,	   UK).	   To	   quantify	   the	  staining,	  27	  microscopic	  fields	  at	  200x	  magnification	  per	  liver	  section	  were	  captured.	  The	  stained	  area	  was	  analyzed	  using	  automated	  Cell-­‐D	   imaging	  software	   (Olympus)	  and	  was	  represented	  as	  %positive	  area	  per	  field.	  
S.4.	  Quantitative	  Real	  Time	  PCR	  Total	  RNA	  from	  liver	  and	  brain	  was	   isolated	  using	  RNeasy	  mini	  kit	   (Qiagen,	  Hilden,	  Germany).	   Total	   RNA	   (1.6µg)	  was	   reverse	   transcribed	   in	   50μl	   using	   cDNA	   synthesis	   kit	  (Promega,	   Madison,	   WI).	   The	   sequences	   of	   primers	   used	   are	   listed	   in	   Supplementary	  
Table	  2	   online.	   The	   reactions	  were	   analyzed	   by	  ABI7900HT	   sequence	   detection	   system	  (Applied	  Biosystems,	  Foster	  City,	  California).	  The	  threshold	  cycles	  (Ct)	  were	  calculated	  and	  relative	  gene	  expression	  was	  analyzed	  after	  normalizing	  for	  GAPDH,	  housekeeping	  gene.	  
S.5.	  Isolation	  of	  primary	  rat	  HSC	  and	  In	  vitro	  binding	  of	  the	  targeted	  IFNγ 	  conjugates	  	  Wistar	   rats	  were	  provided	  by	  Harlan	   (Netherlands)	   and	  maintained	  under	   12:12-­‐h	  light/dark	  cycles	  with	  food	  and	  water	  ad	  libitum.	  HSC	  were	  isolated	  by	  sequential	   in	  situ	  perfusion	   with	   collagenase	   and	   pronase,	   as	   previously	   described	   (3).	   Cells	   were	   plated	  onto	   24-­‐well	   Falcon	   plates	   (Becton	   Dickinson,	   Heidelberg,	   Germany)	   with	   a	   density	   of	  30,000	  cells	  /well.	  Cells	  were	  cultured	   in	  DMEM	  supplemented	  with	  15%	  FCS,	  100	  U/ml	  penicillin,	  100	  μg/ml	  streptomycin,	  and	  1%	  L-­‐glutamine.	  Culture	  medium	  was	  replaced	  2	  days	   after	   plating	   and	   were	   kept	   in	   culture	   at	   37°C	   in	   5%	   CO2	   atmosphere	   and	   100%	  humidity.	  For	  binding	  study,	  at	  day	  10,	  cells	  were	  incubated	  with	  IFNγ	  or	  IFNγ	  conjugates	  (1µg/ml).	  After	  2h,	  cells	  were	  fixed	  and	  immunofluorescent	  staining	  for	  PPB	  and	  IFNγ	  was	  performed.	  	  
SUPPLEMENTARY	  REFERENCES	  	  1.	  	   Beljaars,L.,	  Weert,B.,	  Geerts,A.,	  Meijer,D.K.,	  and	  Poelstra,K.	  2003.	  The	  preferential	  homing	  of	  a	  platelet	   derived	   growth	   factor	   receptor-­‐recognizing	  macromolecule	   to	   fibroblast-­‐like	   cells	   in	  fibrotic	  tissue.	  Biochem.	  Pharmacol.	  66:1307-­‐1317.	  2.	  	   Prakash,J.,	   de,J.E.,	   Post,E.,	   Gouw,A.S.,	   Beljaars,L.,	   and	   Poelstra,K.	   2010.	   A	   novel	   approach	   to	  deliver	   anticancer	   drugs	   to	   key	   cell	   types	   in	   tumors	   using	   a	   PDGF	   receptor-­‐binding	   cyclic	  peptide	  containing	  carrier.	  J.	  Control	  Release.	  145:91-­‐101.	  3.	  	   Geerts,A.,	   Niki,T.,	   Hellemans,K.,	   De,C.D.,	   Van	   Den,B.K.,	   Lazou,J.M.,	   Stange,G.,	   Van	   De,W.M.,	   and	  De,B.P.	   1998.	   Purification	   of	   rat	   hepatic	   stellate	   cells	   by	   side	   scatter-­‐activated	   cell	   sorting.	  
Hepatology.	  27:590-­‐598.	  
	  
	  
